Open AccessAn initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)
Author(s) -
Federico Innocenti,
Chen Jiang,
Alexander B. Sibley,
Stefanie Denning,
Amy S. Etheridge,
Dorothy Watson,
Doniedzwiecki,
Ace J. Hatch,
Herbert I. Hurwitz,
Andrew B. Nixon,
Yoichi Furukawa,
Michiaki Kubo,
Daniel J. Crona,
Hedy L. Kindler,
Howard L. McLeod,
Mark J. Ratain,
Kouros Owzar
Publication year - 2019
Publication title -
pharmacogenetics and genomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.579
H-Index - 140
eISSN - 1744-6880
pISSN - 1744-6872
DOI - 10.1097/fpc.0000000000000375
Subject(s) - gemcitabine , neutropenia , medicine , deoxycytidine , oncology , pancreatic cancer , cancer , chemotherapy
One of the standard of care regimens for advanced pancreatic cancer is gemcitabine-based chemotherapy. The efficacy of gemcitabine is limited by dose-limiting hematologic toxicities especially neutropenia. Uncovering the variability of these toxicities attributed to germline DNA variation is of great importance.